Terns Pharmaceuticals Email Format
Biotechnology ResearchCalifornia, United States51-200 Employees
Terns Pharmaceuticals is a mid-sized biotechnology company headquartered in Foster City, California. It is in the clinical stage of development, pursuing small-molecule candidates aimed at serious diseases, with a focus on oncology and obesity. Its pipeline includes clinical programs such as an allosteric BCR-ABL inhibitor and a GLP-1 receptor agonist, as well as a THR-β agonist. Preclinical programs target GIPR modulation. In 2025, Terns presented positive Phase 1 data for its GLP-1 receptor agonist in obesity at the American Diabetes Association Scientific Sessions. These activities reflect the company's engagement with scientific forums as it advances therapies for cancer and metabolic diseases.